Give people like Harvey genuine hope for the future

Harvey-Moving-Image-v2.png

Give Harvey the opportunity to create years more unforgettable moments with ALECENSA 1L, the only treatment that keeps >60% alive at 5 years, a clinically meaningful improvement vs crizotinib

  • 45 year-old father
  • Runs a small business
  • Enjoys family camping trips
  • Lifelong non-smoker

ALECENSA 1L has a >60% OS rate at 
5 years – the highest of any ALK+ therapy1

survival-graph.jpg

ALECENSA 1L has a >60% OS rate at 5 years – the highest of any ALK+ therapy1

ALEX phase III: 5 year OS
(ITT population)1

chart-superior-survival-1@2x.png

CI: confidence interval; HR: hazard ratio; ITT: intention-to-treat; OS: overall survival.

1. Mok T et al. Ann Oncol. 2020;31(8):1056–64.

CI: confidence interval; HR: hazard ratio; ITT: intention-to-treat; OS: overall survival.

1. Mok T et al. Ann Oncol. 2020;31(8):1056–64.

Continue to

Treatment experience